Industries > Pharma > Dermatological Drugs Market Forecast 2020-2030

Dermatological Drugs Market Forecast 2020-2030

Psoriasis, Skin Infection, Acne, Dermatitis, Others

PUBLISHED: 31 October 2019
PAGES: 355
PRODUCT CODE: PHA0577
SUBMARKET: Therapeutic Drugs

Clear
WOOCS 2.2.1
SKU: PHA0577 Categories: , Tags: , ,

The revenue of the dermatological drugs market in 2018 is estimated at $31bn and is expected to grow at a CAGR of 3.7% in the first half of the forecast period. Psoriasis drugs segment accounted for the largest share of the market in 2018, this segment accounted for 38% of the global dermatological drugs market.

How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 355-page report you will receive 133 tables and 154 figures– all unavailable elsewhere.

The 355-page report provides clear detailed insight into the dermatological drugs market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand-new report today you stay better informed and ready to act.

Report Scope

• Dermatological drugs market forecasts from 2020-2030

• This report also breaks down the revenue forecast for the main submarkets:
• Psoriasis
• Skin Infections
• Acne
• Dermatitis

• Analysis of the Psoriasis drugs market. Revenue forecasts to 2030 are provided for the following drugs:
• Humira
• Stelara
• Enbrel
• Remicade
• Taltz
• Otezla
• Cosentyx

• Analysis of the Skin Infections drugs market. Revenue forecasts to 2030 are provided for the following drugs:
• Cubicin
• Zyvox
• Valtrex
• Canesten
• Lamisil
• Bactroban

Dermatological Drugs Market Forecast 2020-2030

• Analysis of the Acne drugs market. Revenue forecasts to 2030 are provided for the following drugs:
• Solodyn
• Epiduo
• Claravis
• Aczone
• Differin
• Abscorical/Epirus
• Ziana
• Doryx

• Analysis of the Dermatitis drugs market. Revenue forecasts to 2030 are provided for the following drugs:
• Bepanthen/Bepanthol
• Protopic
• Dermovate
• Elocon

• This report provides individual revenue forecasts to 2030 for these regional and national markets:
• North America: US & Canada
• Europe: Germany, France, UK, Italy, Spain, Rest of Europe
• Asia-Pacific: China, Japan, India, Rest of Asia-Pacific
• Latin America: Brazil, Mexico, Rest of Latin America
• Middle East & Africa (MEA): Saudi Arabia, South Africa, Rest of MEA

Each regional market is further segmented by indication: psoriasis, skin infection, acne, dermatitis and others.

• This report provides discussion on pipeline products in various stages of clinical trials and regulatory approval.

• Our study includes SWOT analysis and Porter’s Five Force analysis of the dermatological drugs market.

• Our study discusses the selected leading companies that are the major players in the dermatological drugs market:
• AbbVie
• Allergan
• Amgen
• Bausch Health
• Bayer AG
• Bristol-Myers Squibb
• Celgene Corporation
• Eli Lilly
• Galderma (Nestle Skin Health S.A.)
• GlaxoSmithKline (GSK)
• Johnson & Johnson
• LEO Pharma
• Merck & Co, Inc.
• Novartis
• Pfizer

• Key questions answered by this report:
• How is the dermatological drugs market evolving?
• What is driving and restraining the dermatological drugs market?
• What are the market shares of each segment of the overall dermatological drugs market in 2019?
• How will each dermatological drugs submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2030?
• How will the market shares for each dermatological drugs submarket develop from 2020 to 2030?
• Which individual therapies will prevail and how will these shifts be responded to?
• What will be the main driver for the overall market from 2020 to 2030?
• How will political and regulatory factors influence the regional markets and submarkets?
• Will leading national dermatological drugs markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others?
• How will the market shares of the national markets change by 2030 and which geographical region will lead the market in 2030?
• Who are the leading players and what are their prospects over the forecast period?
• How will the industry evolve during the period between 2019 and 2030?
• Visiongain understands that the dermatological drugs market will register strong growth. This report examines in detail the market by region, by submarket, and as a whole, and provides the reader with a thorough overview of the market to identify key growth areas and business opportunities to exploit. This is where Visiongain adds value.

Visiongain’s study is intended for anyone requiring commercial analyses for the dermatological drugs market. You find data, trends and predictions.

Buy our report today Dermatological Drugs Market Forecast 2020-2030: Psoriasis, Skin Infection, Acne, Dermatitis, Others.

Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6

Do you have any custom requirements we can help you with? Any need for specific country, geo region, market segment or specific company information? Contact us today, we can discuss your needs and see how we can help: sara.peerun@visiongain.com

Download sample pages

Complete the form below to download your free sample pages for Dermatological Drugs Market Forecast 2020-2030


Download sample pages

Complete the form below to download your free sample pages for Dermatological Drugs Market Forecast 2020-2030


Latest Pharma news

Visiongain Publishes Generic Drugs Market Report 2020-2030

The 431-page report provides clear detailed insight into the generic drugs market. Discover the key drivers and challenges affecting the market.

03 July 2020

READ

Visiongain publishes Clinical Workflow Solutions Market Report 2020-2030

Where is the Clinical Workflow Solutions market heading? If you are involved in this sector you must read this newly updated report. Visiongain’s report shows you the potential revenues streams to 2030, assessing data, trends, opportunities and business prospects there.

03 July 2020

READ

Visiongain Publishes Clinical Trials Market Report 2020-2030

With the growing burden of rare diseases around the world, there has been a rise and advancement in the therapy development of these types of diseases. While the fact remains that over 90% of these diseases lack approval for treatment and the total number of terminal rare diseases to receive the first treatment every year remains low.

01 July 2020

READ

Visiongain Publishes Clinical Risk Grouping Solutions Market Report 2020-2030

The market growth is attributed to the growing adoption of big data and AI in data management and monitoring of clinical information in health care.

01 July 2020

READ

Categories

Category